Sign in
Active, not recruitingPhase 2/3

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Key facts

Who runs it
TWi Biotechnology, Inc.
Where
Aurora, Charleston, Chicago, Cincinnati, Rancho Santa Margarita, San Antonio, and Stanford, United StatesSee the 7 sitesAlso in 18 other countries, 28 sites
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
80 people, planned
Started
4 Apr 2024
Expected to end
Mar 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • AC-203
  • Vehicle
Record updated
9 July 2026

Who can take part

Age
6 months to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Patient is at least 6 months old at Visit 2 (Day 1/Baseline A)
  • Patients has been clinically diagnosed with severe EBS or intermediate EBS, confirmed by documented genetic diagnosis to have autosomal dominant mutations in KRT5 or KRT14 gene
  • Patient with ≥ 3% BSA of EBS lesions excluding palms and soles at Visit 2 (Day 1/Baseline A)
  • Patient's EBS lesions within the Treatment Area have an IGA score of ≥3 at Visit 2 (Day 1/Baseline A)
  • Patient/caregiver agrees to follow study medication application instructions
  • Patient (and caregiver/legal guardian) agrees to report use of all prescription and over-the-counter medications, including topical therapies applied to the body, e.g., medical cleansers, bleach cleansers, bleach baths, topical antiseptics, topical disinfectants, etc. for the duration of the study
  • Patient (and caregiver/legal guardian) is willing and able to comply with all study visits and all the protocol requirements, including completing questionnaires
  • Patient (and caregiver/legal guardian) is able to provide written informed consent; assent based on age
  • Female patient of childbearing potential must have a negative pregnancy test prior to randomization
  • Female patient of childbearing potential is willing to practice highly effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per year) from Screening throughout the end of the study

Who cannot take part

  • Patient has a clinically significant underlying medical condition, psychiatric condition (such as major depressive or psychotic disorder, severe intellectual disability, or alcohol or drug use disorder), or requires concomitant medication that based on the investigator's judgement may impair evaluation of the Treatment Area or exposes the patient to an unacceptable risk by study participation
  • Patient has used any diacerein-containing product within 6 months prior to Visit 2 (Day 1/Baseline A)
  • Patient has had a cutaneous infection in the Treatment Area or use systemic antibiotics within 7 days prior to Visit 2 (Day 1/Baseline A)
  • Patient has a current malignancy, or a history of treatment for a malignancy within 5 years (with the exception of treated non-melanoma cutaneous malignancy e.g., surgically resected with clear margins) prior to Visit 2 (Day 1/Baseline A)
  • Patient is treated with protocol-excluded topical therapies other than steroids within 2 weeks prior to Visit 2 (Day 1/Baseline A) that might influence the assessment of the Treatment Area throughout the study period
  • Patient has been treated with topical steroids on the EBS lesions within 2 weeks or systemic steroids within 4 weeks. prior to Visit 2 (Day 1/Baseline A). (Note: inhaled and ophthalmic products containing steroids are allowed.)
  • Patient has been treated with: (a) an approved biologic anti-inflammatory therapy (such as monoclonal antibodies that target to modulate the immune responses) and (b) other immunosuppressive/immunomodulatory therapies or chemotherapy within 8 weeks prior to Visit 2 (Day 1/Baseline A)
  • Patient has been treated with any investigational drug or device within 30 days or 5 half-lives, whichever is longer, prior to Visit 2 (Day 1/Baseline A)
  • Patient has a planned or anticipated major surgical procedure or other activity that would interfere with their ability to comply with protocol requirements
  • Patient has a clinically significant skin disease other than EBS (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or a vascular disorder associated with cutaneous erosions/ulcerations, that may confound assessments of efficacy or safety
  • Patient has a history of allergy or hypersensitivity to any component of study medications, including diacerein or rhein
  • Patient has uncontrolled diabetes mellitus (HbA1c ≥ 6.5%), hepatic enzyme abnormalities (alanine aminotransferase or aspartate aminotransferase >2.5 the upper limit of normal (ULN), or total bilirubin >2.0x ULN), or renal abnormalities (estimated glomerular filtration rate [eGFR]< 30 ml/min/1.73 m2) during the Screening period
  • Patient is pregnant or breastfeeding/lactating

Where in United States

Also in 18 other countries, 28 sites

  • Children's Hospital ColoradoAurora, United States
  • Medical University of South CarolinaCharleston, United States
  • Northwestern University - Lurie Childrens's HospitalChicago, United States
  • Cincinnati Childrens HospitalCincinnati, United States
  • Mission Dermatology CenterRancho Santa Margarita, United States
  • Texas Dermatology and Laser SpecialistsSan Antonio, United States
  • Stanford UniversityStanford, United States

About the trial

What the trial wants to find out

The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.

The 3 groups in the trial

  • Part A AC-203Treatment being tested

    Double-blind, AC-203 Diacerein 1% ointment, QD

    Treatment: AC-203

  • Part A Vehicle ointmentPlacebo, for comparison

    Double-blind, Vehicle ointment, QD

    Treatment: Vehicle

  • Part B AC-203Treatment being tested

    Open-label extension phase, AC-203 Diacerein 1% ointment, QD

    Treatment: AC-203

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]
Record updated
9 July 2026